10% off for first time customers! Use code “daytrypfirst” at checkout.
Ketamine has moved from an anesthetic used in operating rooms to a closely studied option for treatment-resistant depression. However, not all ketamine treatments are the same. Esketamine and racemic ketamine share a chemical relationship, yet they differ in composition, FDA status, administration, clinical evidence, and access.
This article breaks down how they differ chemically, how their clinical evidence compares, what FDA approval means for each option, and how treatment access can vary.
Racemic ketamine contains two mirror-image molecules, or enantiomers: R-ketamine and S-ketamine. Esketamine is the S-enantiomer alone. Both interact with the NMDA receptor system involved in glutamate signaling, although the precise mechanism behind their antidepressant effects is still being studied.
The distinction matters because esketamine nasal spray is an FDA-approved prescription treatment for specific indications, including treatment-resistant depression in adults. Racemic ketamine, meanwhile, is FDA-approved as an anesthetic, not specifically as a treatment for depression. Its psychiatric use is therefore considered off-label.
Both treatments have demonstrated rapid antidepressant effects. A 2022 study found that ketamine treatments overall were associated with improved response, remission, and depression severity compared with placebo.
The two treatments may work about the same in the short term. In one study of 63 people with treatment-resistant depression, about 24% of people who received racemic ketamine were in remission after 24 hours, compared with about 29% of those who received esketamine. The researchers found that esketamine worked at least as well as ketamine in that study.
However, the evidence base is not identical. Esketamine has undergone the clinical trials and regulatory review required for its FDA-approved indications, while much of the evidence for racemic ketamine in depression involves off-label administration, particularly intravenous treatment.
Access can look very different. FDA-approved esketamine must be administered under the requirements of the Spravato REMS program, with monitoring for at least two hours after administration because of risks including sedation, dissociation, and respiratory depression.
Racemic ketamine may be prescribed off-label through appropriately licensed medical providers, including some telehealth-based programs. However, protocols, eligibility requirements, formulations, and monitoring can vary considerably.
This means searches for ketamine therapy from home should lead to questions about medical supervision, prescribing practices, screening, and follow-up, not simply convenience or price.
The right ketamine treatment is not simply about choosing a medication. It also involves considering the formulation, route of administration, medical oversight, follow-up, and whether the approach fits your individual needs. For people interested in home-based ketamine treatment, having access to qualified clinical support can be especially important.
Daytryp RX offers telehealth-based ketamine therapy from home for qualified patients, with both ketamine troches and nasal spray options available. The program begins with an initial medical consultation, followed by optional provider follow-ups, integrated health coaching, and ongoing customer support.
Explore your ketamine treatment options from home; contact us today.
